Lilly Opens ADA With Head-To-Head Dulaglutide/Liraglutide Data
Executive Summary
Lilly’s once-weekly GLP-1 demonstrated non-inferiority to the once-daily market leader, Novo Nordisk’s Victoza, on blood sugar control, but the weight loss with Victoza was statistically greater.